What is HC Wainwright’s Estimate for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Thursday, March 26th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.00) per share for the quarter, up from their previous estimate of ($1.04). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.16) EPS.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Tuesday, March 24th. The company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.08.

Several other research firms also recently commented on NGNE. Canaccord Genuity Group began coverage on Neurogene in a research note on Friday, February 27th. They issued a “buy” rating for the company. Lifesci Capital began coverage on shares of Neurogene in a report on Monday, January 26th. They set an “outperform” rating and a $50.00 target price for the company. Wall Street Zen cut shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Price Performance

Shares of NASDAQ:NGNE opened at $20.35 on Monday. The business’s 50 day moving average price is $19.52 and its 200-day moving average price is $21.69. The firm has a market capitalization of $316.85 million, a PE ratio of -4.80 and a beta of 1.53. Neurogene has a 1 year low of $6.88 and a 1 year high of $37.27.

Insiders Place Their Bets

In other news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the transaction, the insider owned 30,497 shares in the company, valued at $634,642.57. The trade was a 18.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the transaction, the chief financial officer directly owned 105,798 shares in the company, valued at approximately $2,201,656.38. The trade was a 3.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 9.92% of the company’s stock.

Hedge Funds Weigh In On Neurogene

A number of institutional investors have recently bought and sold shares of the company. Virtus Investment Advisers LLC boosted its holdings in Neurogene by 128.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock valued at $262,000 after purchasing an additional 7,138 shares during the last quarter. Logos Global Management LP acquired a new stake in shares of Neurogene during the 4th quarter worth approximately $4,017,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Neurogene during the 4th quarter valued at approximately $575,000. Trexquant Investment LP raised its position in shares of Neurogene by 9.7% during the 4th quarter. Trexquant Investment LP now owns 43,323 shares of the company’s stock valued at $892,000 after buying an additional 3,840 shares during the period. Finally, Blair William & Co. IL lifted its holdings in Neurogene by 15.4% in the fourth quarter. Blair William & Co. IL now owns 163,655 shares of the company’s stock valued at $3,371,000 after acquiring an additional 21,835 shares during the last quarter. 52.37% of the stock is owned by hedge funds and other institutional investors.

Key Neurogene News

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $70 price objective for NGNE, providing bullish analyst support even as it modeled FY2027 EPS of ($4.93). This endorsement and high target can help underpin longer-term upside. HC Wainwright Buy/$70 Target
• Positive Sentiment: An MSN/aggregated report flagged a substantial analyst-driven price-target increase (reported as a 37.29% rise to 82.62), signaling at least one firm is materially more optimistic on Neurogene’s longer-term value — a clear positive for investor sentiment and potential catalyst for upside. Neurogene (NGNE) price target increased by 37.29% to 82.62
• Neutral Sentiment: A Globe and Mail roundup included Neurogene in a broader analysts-insights piece; such coverage can raise visibility but didn’t add new company-specific data likely to move the stock by itself. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Lifesci Capital cut Q1–Q4 2026 and FY2026 EPS estimates for NGNE across multiple notes, lowering FY2026 EPS to ($4.59) (from $4.33) while still keeping an “Outperform” rating and a $50 target. Those downward revisions to near-term profitability are a bearish driver and likely the primary reason for today’s weakness. Lifesci Capital EPS revisions / Outperform $50

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.